Recent Updates
Recently added Catalysts

CHI-554

Phase 2

Anxiety | Small molecule | Psychiatry |Canopy Growth Corporation Common Shares|Last Updated: Jun 2, 2021

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment84
FDA Designations
No designations recorded
Clinical trial landscape

CHI-554 · 1 trial · 3 indications

Phase 2 1
NCT04577612A Randomized Controlled Test of the Effects of CHI-554 on Fear.Anxiety
COMPLETED84 Analytics
PHASE2COMPLETED
A Randomized Controlled Test of the Effects of CHI-554 on Fear.
Anxiety
NCT0457761284
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
CHI-554DRUGhemp-derived CBD in MCT oil
Unlock Study Design Details
Competitive Landscape -Anxiety Disorders 31 trials (matched to "Anxiety")
CompanyTickerTrialsLead PhaseDrugs
Definium Therapeutics, Inc.DFTX2PHASE3DT120
Vistagen Therapeutics, Inc.VTGN3PHASE3Fasedienol
Vanda Pharmaceuticals Inc.VNDA1PHASE3VQW-765
AbbVie, Inc.ABBV1PHASE2ABBV-932, Antidepressant Therapy
Cybin, Inc.HELP1PHASE2CYB004
Co-Diagnostics, Inc.CODX1PHASE2ONO-1110
Masimo CorporationMASI1PHASE1Diprivan , Astra-Zeneca
Psyence Biomedical Ltd.PBM1PHASE2Psilocybin therapy
Neuronetics, Inc.STIM2 - Undisclosed
Aura Biosciences IncAURA1 - Undisclosed
Cooper Companies, Inc.COO1N/AUndisclosed
Vera Therapeutics, Inc. Class AVERA1N/AUndisclosed
Design Therapeutics, Inc.DSGN1N/AUndisclosed
Unlock Competitive Intelligence